Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess a maximal tolerable dose and to assess the safety of a
chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-fluorouracil
(5-FU)/folinic acid (FA) as first-line treatment for metastatic colorectal cancer.